| 2.68 -0.09 (-3.25%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.87 | 1-year : | 4.38 |
| Resists | First : | 3.31 | Second : | 3.75 |
| Pivot price | 2.97 |
|||
| Supports | First : | 2.6 | Second : | 2.17 |
| MAs | MA(5) : | 2.75 | MA(20) : | 3 |
| MA(100) : | 3.5 |
MA(250) : | 3.8  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 19.1 |
D(3) : | 22 |
| RSI | RSI(14): 34.1 |
|||
| 52-week | High : | 6.55 | Low : | 2.43 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SANA ] has closed above bottom band by 14.6%. Bollinger Bands are 8.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.86 - 2.87 | 2.87 - 2.89 |
| Low: | 2.63 - 2.65 | 2.65 - 2.67 |
| Close: | 2.65 - 2.68 | 2.68 - 2.71 |
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
Fri, 12 Jun 2026
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.14, Implies 230% Upside - TradingView
Mon, 08 Jun 2026
Sana Biotechnology, Inc. - MLQ.ai
Sat, 06 Jun 2026
SANA SEC Filings - Sana Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Fri, 05 Jun 2026
Sana Biotechnology (SANA) director awarded options for 90,000 shares at $2.96 - Stock Titan
Fri, 05 Jun 2026
Director Michelle Seitz gets 90,000 Sana (SANA) stock options - Stock Titan
Tue, 02 Jun 2026
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 278 (M) |
| Shares Float | 170 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 82.8 (%) |
| Shares Short | 38,470 (K) |
| Shares Short P.Month | 40,880 (K) |
| EPS | -0.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.6 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.5 % |
| Return on Equity (ttm) | -147.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -133 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -2.92 |
| PEG Ratio | 0 |
| Price to Book value | 4.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|